Search
Over 100 researchers and health professionals from around Australia have united in Broome this week to address the major health battles facing people living in the tropical north of the country.
Leading paediatrician, infectious diseases specialist and Executive Director of The Kids Research Institute Australia, Professor Jonathan Carapetis, has been recognised for his significant contribution towards medical research with the award of Member of the Order of Australia (AM).
The World Health Organisation resolution for global action to tackle rheumatic heart disease (RHD) will have significant implications for Australia, which has some of the highest rates of the disease in the world.
In a WA first, researchers from The Kids Research Institute Australia have shown that Aboriginal babies are 22.5 times more likely to be treated for skin infections than non-Aboriginal babies.
Some of the nation’s leading medical researchers will converge on Darwin this week to step out a plan to wipe out rheumatic heart disease.
Here we describe the experiences of young people living with ARF participating in a Phase-II trial of SubCutaneous Injections of BPG.
Rheumatic heart disease (RHD) is the most common form of acquired heart disease worldwide. In RHD, volume loading from mitral regurgitation leads to left ventricular (LV) dilatation, increased wall stress, and ultimately LV dysfunction. Improved understanding of LV dynamics may contribute to refined timing of intervention.
Scabies is one of the world’s most prevalent diseases, with approximately 147 million cases at any one time and an estimated annual incidence of 455 million new episodes. Although Group A streptococcal (GAS) pharyngitis has long been implicated in the pathogenesis of acute rheumatic fever (ARF) and subsequent rheumatic heart disease (RHD), impetigo caused by GAS has recently been postulated as a link between scabies and the pathogenesis of ARF.
Group A Streptococcus causes a wide range of diseases from relatively mild infections including pharyngitis to more severe illnesses such as invasive diseases and rheumatic heart disease (RHD). Our aim is to estimate the cost-effectiveness of a hypothetical Strep A vaccine on multiple disease manifestations at the global-level.
Primary prevention of acute rheumatic fever (ARF) and rheumatic heart disease (RHD) encompasses the timely diagnosis and adequate treatment of the superficial group A Streptococcus (GAS) infections pharyngitis and impetigo. GAS is the only known inciting agent in the pathophysiology of the disease.